Integrated health system pharmacy role in adherence, persistence, and adverse effect management for oral chronic lymphocytic leukemia therapy.
In a population of patients initiating oral CLL/SLL therapy through an integrated health system specialty pharmacy, adherence and persistence to therapy was high. Adverse effects were attributed in 36% of therapy discontinuations and 72% of therapy switches, indicating a continued opportunity for specialty pharmacists to help manage and mitigate adverse effects. Pharmacist interventions were common and sometimes resulted in therapy changes.
Authors
- Hannah Holloway
- Chelsea P. Renfro (ORCID: https://orcid.org/0000-0002-4090-8457)
- Autumn D. Zuckerman (ORCID: https://orcid.org/0000-0002-8376-0691)
- Leena Choi (ORCID: https://orcid.org/0000-0002-2544-7090)
- Keri Yang
- Josh DeClercq (ORCID: https://orcid.org/0000-0002-8171-5766)
- Stephanie White (ORCID: https://orcid.org/0000-0002-5550-6397)
- Houston Wyatt (ORCID: https://orcid.org/0000-0003-3179-7182)
- Mei Xue
- Karen Carr (ORCID: https://orcid.org/0000-0002-5870-1219)
- Swetha Challgulla
Institutions
- United States Department of Veterans Affairs (US)
- Vanderbilt Health (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- PubMed
- Published
- 2025-03-01
- DOI
- https://doi.org/10.18553/jmcp.2025.31.3.253
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00